Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-based treatment in children with steroid-resistant nephrotic syndrome
IRCT20150421021894N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab, mycophenolate mofetil and cyclophosphamide in nephrosis and focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Proportion of patients responding to treatment, Time in remission and 1 more. Started Apr 2010; status: completed.
02
Drugs
rituximabmycophenolate mofetilcyclophosphamide
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on IRCT20150421021894N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150421021894N1.